Annals of the rheumatic diseases
POS0391 THE MSQUASH AS MEASUREMENT TOOL FOR DAILY PHYSICAL ACTIVITY: TRANSLATION AND CROSS-CULTURAL ADAPTATION INTO ENGLISH, FIELD-TESTING IN DIFFERENT RHEUMATIC DISEASES AND CLINICAL VALIDATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS.
POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION.
AB0913 EFFICACY OF CERTOLIZUMAB PEGOL IN PREVENTING ANTERIOR UVEITIS FLARES COMPARED WITH STANDARD NON-BIOLOGIC TREATMENT: A MATCHED CONTROL STUDY IN HIGH-RISK PATIENTS WITH AXIAL SPONDYLOARTHRITIS.
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity.
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
ASAS consensus definition of early axial spondyloarthritis.
POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS.
OP0243 PROTON PUMP INHIBITOR USE IS ASSOCIATED WITH IMPAIRED BONE MINERAL DENSITY BUT NOT BONE MICROARCHITECTURE IN PATIENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES TAKING GLUCOCORTICOIDS.
POS0823 UPTAKE OF INFLIXIMAB BIOSIMILARS AMONG U.S. RHEUMATOLOGY PRACTICES THROUGH 2022.
